Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Free Cash Flow (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Free Cash Flow data on record, last reported at -$287.0 million in Q1 2026.

  • On a quarterly basis, Free Cash Flow fell 68.64% to -$287.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$779.9 million, a 65.53% decrease, with the full-year FY2025 number at -$663.1 million, down 42.36% from a year prior.
  • Free Cash Flow reached -$287.0 million in Q1 2026 per PCVX's latest filing, down from -$226.8 million in the prior quarter.
  • Over the last five years, Free Cash Flow for PCVX hit a ceiling of -$30.6 million in Q1 2022 and a floor of -$287.0 million in Q1 2026.
  • A 5-year average of -$112.1 million and a median of -$106.2 million in 2024 define the central range for Free Cash Flow.
  • On a YoY basis, Free Cash Flow climbed as much as 20.8% in 2024 and fell as far as 245.16% in 2024.
  • Tracing PCVX's Free Cash Flow over 5 years: stood at -$66.4 million in 2022, then tumbled by 102.02% to -$134.1 million in 2023, then increased by 20.8% to -$106.2 million in 2024, then plummeted by 113.61% to -$226.8 million in 2025, then fell by 26.53% to -$287.0 million in 2026.
  • Business Quant data shows Free Cash Flow for PCVX at -$287.0 million in Q1 2026, -$226.8 million in Q4 2025, and -$145.4 million in Q3 2025.